The global cancer biomarker market is anticipated to grow at a CAGR of 11.32% between 2019 and 2027. The cancer biomarkers are traceable substances, molecules, or a physical event that indicate the existence of cancerous cells in the body. The cancer biomarker market is mainly driven by the following factors:

• Adoption of western lifestyles in the developing regions
• Encouragement for biomarker development by FDA
• Growth in the importance of biological and targeted drug therapies
• Growing prevalence on the research of cancer biomarkers
• Technological advancements
• Improved precision and speed of diagnosis
• High investment through government and private funds in cancer-related research
• Development of highly specific drugs
• Growing personalized medicine and companion diagnostics

To know more about this report, request a free sample copy

The important drivers increasing growth in the global cancer biomarker market is the growing prevalence on the research of cancer biomarkers and growing personalized medicine and companion diagnostics. The rising research projects related to cancer biomarkers is anticipated to improve the clinical efficacy and to invent new techniques for the detection of cancer in the initial stage. The personalized medicines hold tremendous opportunities for the growth of the cancer biomarkers market by developing suitable treatment solutions as per an individual’s need.

Cancer profiling technology and applications are useful in cancer biomarker. Profiling technology includes Omic Technology, Imaging Technologies, Immunoassays and Cytogenetic-Based Tests. Whereas, applications segment comprises diagnostics, drug discovery and development, prognostics, risk assessment and other application. Omic technologies are high-throughput technologies utilized to measure and evaluate the different types of cellular molecules. Imaging biomarkers are important tools used to detect and characterize cancer as well as to monitor the response of the therapy. Immunoassay testing has been used to diagnose various infectious diseases, oncological detection, HIV/AIDS virus detection, and others. Diagnostic biomarkers are used to determine the presence or absence of cancer. Cancer biomarkers are used for the disease prognosis, which is carried out after the diagnosis of cancer. Cancer biomarkers are quantitative indicators used for evaluating various aspects of disease progression.

The low estimated rate of successful clinical trials of biomarkers and the high cost of drug development are the major factors hampering the cancer biomarker market. There are high investment and low benefit-cost ratio related to the growth of cancer biomarkers which is also creating major limitations to the market. Also, the cost of new drug development is very high and not affordable for small and medium-sized organizations, which limits their entry into the market.

The global cancer biomarker market segments include profiling, biomarker, cancer type and application.

Profiling is segmented into:

• Omics technology
  • Genomics
    • Next-generation sequencing (NGS)
    • Microarray
    • Polymerase chain reaction (PCR)
  • Proteomics
    • Mass spectrometry
    • 2D gel electrophoresis
    • Protein microarray technology
    • Antibody array technology
    • Peptide array technology
  • Other omic technologies
    • Metabolomics
    • Glycomics
  • Imaging technologies
    • Magnetic resonance imaging (MRI)
    • Positron emission tomography (PET)
    • Computed tomography
    • Mammography
    • Ultrasound
  • Immunoassays
    • Immunohistochemistry (IHC) tests
    • Enzyme-linked immunosorbent assay (ELISA)
    • Flow cytometry
  • Cytogenetic-based tests
    • In situ hybridization
    • Others cytogenetic-based tests

Biomarker is segmented into:

• Genetic biomarkers
• Protein biomarkers
• Glyco biomarkers

Cancer type is segmented into:

• Lung cancer
• Breast cancer
• Colorectal cancer
• Prostate cancer
• Stomach cancer
• Others cancer type

Application is segmented into:

• Diagnostics
• Drug discovery and development
• Prognostics
• Risk assessment
• Other application

This report covers the present market conditions and the growth prospects of the global cancer biomarker market for 2019-2027, considering the revenue generated through the sales of cancer biomarker tools for profiling, biomarker, cancer type, and application to calculate the market size by considering 2018 as the base year.

Geographically, the global cancer biomarker market has been segmented on the basis of four major regions, which include:

• Cancer Biomarker North America Market – The United States & Canada
• Cancer Biomarker Asia-Pacific Market – China, India, Japan, South Korea, Australia & Rest of APAC
• Cancer Biomarker Europe Market – The United Kingdom, France, Germany, Spain, Italy & Rest of Europe
• Rest of World- Latin America & Middle East and Africa

The cancer biomarker market in North America is expected to hold the largest share by 2027 due to developed economies such as the United States and Canada and the high prevalence of cancer. The region is also making investments considering the detection and diagnosis of cancer. The United States is the leading country in the North America cancer biomarkers market. The United States is the dominating market due to increased demand for investment in research and development, the growing prevalence of cancer and medical tourism.

On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region in the cancer biomarker market. The growing population in countries such as China and India, rising investments by public and private sectors in the cancer diagnosis and treatment as well as the growing prevalence rate of cancer in the Asia-Pacific region is expanding the cancer biomarkers market in the Asia-Pacific region. In addition, the rise in medical tourism considering the cancer diagnosis and treatment is also impacting the market growth in the region.

The cancer biomarker market is segmented into biomarker which is sub-divided into Genetic Biomarkers, Protein Biomarkers & Glyco Biomarkers. The market is segmented on the basis of cancer type which is sub-divided into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer & Others Cancer Type.

The major market players in the global cancer biomarker market are:

• Abbott Laboratories
• Roche Diagnostics Ltd.
• Qiagen NV.
• Beckamn Coulter
• Aureon Laboratories Inc.

Company Profiles covers analysis of important players.

Abbott Laboratories (Abbott) is a U.S. based company, headquartered in Illinois. The company discovers, develop, manufacture and sell a line of health care products. The company majorly operates in four business segments: vascular products, nutritional products, diagnostic products, and established pharmaceutical products. Aureon Biosciences, Inc. is the United States based life sciences company having headquarters in Yonkers, New York. The company offers advanced personalized and predictive cancer treatment options. The prognostic tests include Prostate Px and Post-Op Px. The company prognostic tools offer risk assessment at diagnosis and after surgery.

Key Findings of the global cancer biomarker market:

• Omics technology generated the highest revenue in terms of profiling technology
• Glyco biomarkers are the fastest growing cancer biomarkers
• Breast cancer holds the largest market share in terms of cancer type
• Diagnostics application is the majorly used cancer biomarker application